...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Psoriasis: Targets and Therapy >Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
【24h】

Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry

机译：英夫利昔单抗的低起始剂量可能会增加银屑病关节炎的剂量，其治疗效果与阿达木单抗或依那西普的标准剂量相同：来自全国冰岛ICEBIO注册表的结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA). Methods: Biologically na?ve PsA patients who were beginning anti-TNF-α therapy were selected from the ICEBIO registry. Demographics and clinical differences were compared in four treatment groups: infliximab 4 mg/kg; etanercept or adalimumab at baseline and on follow-up (6 and 12 months, last visit). The Kruskal–Wallis rank sum test was used for comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens. Results: One hundred and eighty-five patients (61% female) were identified; 84 patients received infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up. Conclusion: In respect to treatment effects, a low dosage of infliximab with possible escalating dosage is acceptable for the majority of PsA patients who are in need of biological treatment.
机译：目的：探讨银屑病关节炎（PsA）患者与标准剂量的依那西普和阿达木单抗相比，低剂量的英夫利昔单抗方案与递增剂量的疗效差异。方法：从ICEBIO注册中心中选择开始接受抗TNF-α治疗的生物学纯朴的PsA患者。比较了四个治疗组的人口统计学和临床​​差异：英夫利昔单抗4 mg / kg;基线和随访时（6个月和12个月，最后一次访视）依那西普或阿达木单抗。 Kruskal–Wallis秩和检验用于比较各组，Wilcoxon检验用于比较两种英夫利昔单抗剂量方案。结果：确定了一百八十五名患者（61％为女性）; 84例患者接受了英夫利昔单抗，66种依那西普和35例阿达木单抗。英夫利昔单抗治疗的患者总数中有19％的剂量增加了≥4mg / kg。在基线时，在视觉模拟评分（VAS）疼痛，VAS疲劳，健康评估问卷，C反应蛋白（CRP），关节肿胀或触痛的数量或疾病活动评分（DAS）28-CRP方面，未观察到显着差异价值观。随访中所有四个治疗组均观察到相似的治疗反应。结论：就治疗效果而言，低剂量的英夫利昔单抗和可能增加的剂量对于大多数需要进行生物治疗的PsA患者是可以接受的。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号